Defitelio (Defibrotide Sodium): Uses, Side Effects & Warnings

• Defitelio is approved for treating hepatic veno-occlusive disease (VOD) with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation.
• It works by protecting endothelial cells and enhancing fibrinolytic activity, helping to restore blood flow in affected liver vessels.
• Common side effects include hemorrhage, hypotension, and gastrointestinal disturbances. Serious warnings include a significant risk of bleeding.
• Patients receiving Defitelio require close monitoring for bleeding and other adverse reactions.
• The medication is administered intravenously, and treatment duration depends on the patient’s clinical response.

What is Defitelio (Defibrotide Sodium) Used For?

Defitelio (defibrotide sodium) is a vital medication indicated for the treatment of hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT). This severe complication can arise after high-dose chemotherapy and radiation used in HSCT, leading to damage to the small blood vessels in the liver. Hepatic VOD is characterized by obstruction of the hepatic sinusoids, which can lead to liver failure, multi-organ dysfunction, and high mortality rates.

The primary Defitelio uses and indications are specifically for patients who have already developed VOD with significant organ dysfunction. This condition is particularly challenging to manage, and severe VOD can have a mortality rate exceeding 80% without effective intervention, according to clinical studies. Defitelio offers a targeted therapeutic approach to address the underlying vascular damage. The Defitelio treatment details involve intravenous administration, typically for a duration determined by the patient’s clinical response and resolution of VOD symptoms.

How Defibrotide Sodium Works

The therapeutic efficacy of Defitelio stems from its unique Defibrotide sodium mechanism of action. Defibrotide sodium is a complex mixture of single-stranded deoxyribonucleotides. Its primary action involves modulating the function of endothelial cells, which line the interior surface of blood vessels. In VOD, these endothelial cells become damaged, leading to inflammation, thrombosis, and obstruction of the liver’s sinusoids.

Defibrotide sodium works by protecting these damaged endothelial cells and restoring their normal function. It enhances the activity of fibrinolytic enzymes, which are responsible for breaking down blood clots, thereby helping to clear the obstructions in the hepatic sinusoids. Additionally, it exhibits anti-inflammatory and anti-thrombotic properties, reducing the overall damage and improving microvascular blood flow within the liver. This multifaceted approach helps to mitigate the progression of VOD and supports the recovery of liver function in affected patients.

Defitelio (Defibrotide Sodium) Side Effects and Warnings

While Defitelio is crucial for treating severe VOD, it is associated with potential adverse effects and important warnings that healthcare providers and patients must be aware of. The most significant concern related to Defibrotide sodium side effects is the risk of hemorrhage. Due to its impact on the coagulation system, Defitelio can increase the likelihood of bleeding, which can range from mild to severe and life-threatening.

Commonly reported side effects include hypotension (low blood pressure), gastrointestinal hemorrhage, epistaxis (nosebleed), hemoptysis (coughing up blood), and other bleeding events. Patients may also experience nausea, vomiting, diarrhea, and fever. It is critical for medical professionals to monitor patients closely for any signs of bleeding throughout the treatment course. The Defitelio drug warnings and precautions emphasize that Defitelio should not be initiated in patients with active bleeding or who are at high risk of bleeding, such as those with severe thrombocytopenia or coagulopathy, unless the benefits clearly outweigh the risks.

Common Side Effects

• Hemorrhage (e.g., gastrointestinal, pulmonary, cerebral)
• Hypotension
• Nausea and vomiting
• Diarrhea
• Sepsis
• Headache
• Epistaxis (nosebleed)
• Rash

Serious Warnings and Precautions

Beyond common side effects, several serious warnings are associated with Defitelio. The most critical is the risk of serious and fatal hemorrhage. This includes gastrointestinal, pulmonary, and cerebral hemorrhage. Concomitant use of other anticoagulant or fibrinolytic agents may further increase this risk. Therefore, careful consideration and close monitoring are essential when Defitelio is administered with such medications. Additionally, hypersensitivity reactions, including anaphylaxis, have been reported. Patients should be monitored for signs of allergic reactions, and appropriate medical management should be available.

Important Patient Information for Defitelio Treatment

For individuals undergoing treatment with Defitelio, understanding key aspects of their care is paramount. Defitelio patient information covers what to expect before, during, and after administration. Patients should be informed about the purpose of the medication, its potential benefits in treating VOD, and the serious risks involved, particularly the risk of bleeding. It is crucial for patients to report any signs of bleeding immediately to their healthcare team, such as unusual bruising, prolonged bleeding from cuts, blood in urine or stools, or severe headaches.

Defitelio is administered intravenously in a hospital setting, requiring close medical supervision. The duration of treatment typically continues until VOD symptoms resolve or for a maximum of 21 days, though this can be extended based on clinical judgment. Regular monitoring of blood counts, liver function, and kidney function is essential throughout the treatment period to assess the patient’s response and detect any adverse effects early. Patients should also be aware that Defitelio is not a preventive measure for VOD but a treatment for established disease with organ dysfunction.

Frequently Asked Questions

How is Defitelio administered?

Defitelio is administered as an intravenous (IV) infusion, typically in a hospital setting under close medical supervision. The medication is given over a specific period, usually two hours, multiple times a day. The dosage and frequency are determined by the patient’s weight and clinical condition. Healthcare providers will monitor the patient for any immediate reactions during the infusion and for potential side effects throughout the treatment course to ensure safety and efficacy.

What are the most serious risks associated with Defitelio?

The most serious risk associated with Defitelio is hemorrhage, which can be severe or even fatal. This includes bleeding in the gastrointestinal tract, lungs, or brain. Patients are closely monitored for signs of bleeding, such as unusual bruising, blood in urine or stool, or severe headaches. Other serious risks include hypersensitivity reactions, which may manifest as allergic responses. Healthcare providers carefully weigh these risks against the life-saving benefits of the treatment for severe VOD.

Who is Defitelio prescribed for?

Defitelio is specifically prescribed for adult and pediatric patients who have developed severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT). It is not indicated for the prevention of VOD. The diagnosis of VOD with organ dysfunction is critical for its appropriate use, as this condition carries a high mortality rate without effective treatment.